Categories: All News

News: Apotex Corp Recalls Enoxaparin Sodium Injection USP due to Mislabelling of Syringe Barrel Measurement Markings

The National Agency for Food and Drug Administration and Control (NAFDAC) has received information from the US FDA that Apotex Corp is voluntarily recalling two (2) batches of Enoxaparin Sodium Injection, USP due to a packaging error resulting in some syringes barrels containing 150 mg/mL markings (corresponding to 120 mg/0.8mL strength) instead of 100 mg/mL markings (corresponding to 100 mg/mL strength) on the syringe barrel and vice versa.


Enoxaparin Sodium injection is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), Treatment of Acute Deep Vein Thrombosis, prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin and Treatment of Acute ST-Segment Elevation Myocardial Infarction.

Incorrect syringe barrel marking could lead to miscalculation and inaccurate dose administration to patients. Accidental overdosage following administration of enoxaparin sodium injection may lead to bleeding complications. Alternatively, if the dose administered is less than prescribed, the patient may be subject to developing some blood clotting conditions.

Product details

The affected Enoxaparin Sodium Injection, USP is manufactured by manufactured by Gland Pharma Limited, Hyderabad, India and has the following details:

Product Enoxaparin Sodium Injection, USP
Batch # CS008 CT003
Strength 100 mg/mL 120 mg/0.8mL
Syringe Barrel Measurement Markings 100 mg/mL 150 mg/ mL
Pack Size 10 x 1mL Single Dose Syringes 10 x 0.8 mL Single Dose Syringes
NDC Number on Carton 60505-0795-4 60505-0796-4
NDC Number On label 60505-0795-1 60505-0796-0
UPC Code on Carton 360505079544 360505079643
UPC Code on label (01)10360505079510 (01)10360505079602

Recommendations


Healthcare providers with an existing stock of the recalled products are encouraged to:

  • Stop dispensing or distributing the products immediately and quarantine the products.
  • Return unused products to the nearest NAFDAC office for regulatory action.
Vivian Omotori

Recent Posts

Pre-pack sales to face mandatory independent scrutiny

New laws will require mandatory independent scrutiny of pre-pack administration sales where connected parties -… Read More

February 28, 2021

Major habitat creation project on the Humber to start this spring

Work on a major project on the Humber will start this spring to realign existing… Read More

February 28, 2021

Surge testing to be deployed in targeted areas in Redbridge

Working in partnership with the local authority, additional testing and genomic sequencing is being deployed… Read More

February 28, 2021

This website uses cookies.